Cancer Drug Parity Act of 2023

House Bill 6301 - Cancer Drug Parity Act of 2023: Overview, Status, and Impact

Hozzl · 2024-03-14T04:05:17Z

Explore the details of House Bill 6301 Cancer Drug Parity Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/14/2024, 4:05 AM

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 6301

Bill HR 6301 is currently in the status of Bill Introduced since November 8, 2023. Bill HR 6301 was introduced during Congress 118 and was introduced to the House on November 8, 2023. Bill HR 6301's most recent activity was Referred to the House Committee on Education and the Workforce. as of November 8, 2023

Bipartisan Support of Bill HR 6301

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 6301

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 6301

Cancer Drug Parity Act of 2023

To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider.